Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
+0.25 (1.22%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.50 - 20.99
52 week 18.45 - 23.24
Open 20.78
Vol / Avg. 0.00/2.20M
Mkt cap 5.69B
P/E     -
Div/yield     -
EPS -4.36
Shares 274.39M
Beta 1.21
Inst. own 101%
Apr 30, 2014
Q2 2014 Hologic Earnings Conference Call - 5:00PM EDT - Add to calendar
Apr 30, 2014
Q2 2014 Hologic Earnings Release - 4:00PM EDT - Add to calendar
Mar 4, 2014
Hologic Annual Shareholder Meeting
Feb 3, 2014
Q1 2014 Hologic Earnings Conference Call - Webcast
Feb 3, 2014
Q1 2014 Hologic Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -0.87% -47.06%
Operating margin 9.53% -36.73%
EBITD margin - 19.34%
Return on average assets -0.25% -12.04%
Return on average equity -1.10% -47.85%
Employees 5,615 -
CDP Score - -


35 Crosby Drive
United States - Map
+1-781-9997300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women. The Company's core business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company sells and service its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company offers a wide range of diagnostic products which are used primarily to aid in the diagnosis of human diseases and screen donated human blood. The Company's molecular diagnostics products include the Company's Aptima family of assays based on its Transcription-Mediated-Amplification, or TMA, technology, its Cervista products based on its Invader chemistry and its advanced instrumentation (Panther, Tigris and HTA).

Officers and directors

David R. LaVance Jr. Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Stephen P. MacMillan President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Glenn P. Muir Chief Financial Officer, Executive Vice President - Finance and Administration, Assistant Treasurer, Assistant Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Casey Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Rohan F. Hastie Ph.D. Group Senior Vice President, General Manager - Diagnostics
Age: 39
Bio & Compensation  - Reuters
Roger D. Mills Group Senior Vice President, General Manager - Service and Operations
Age: 58
Bio & Compensation  - Reuters
David P. Harding Senior Vice President - Corporate Strategy
Age: 48
Bio & Compensation  - Reuters
Jonathan N. Christodoro Independent Director
Age: 36
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 59
Bio & Compensation  - Reuters